ABSTRACT
INTRODUCTION
Globally, the World Health Organization (WHO) reports that as many as 220 million individuals have diabetes. 1 The Framingham Offspring Study diabetes mellitus (DM2) has doubled in the US from the 1970s through the 1990s. 2 In the US, it was estimated in 2010 that nearly 26 million individuals had diabetes, of which 7.0 million (27%) were undiagnosed. 3 Furthermore, the prevalence of diabetes (driven largely by DM2) is projected to reach 12.0% by 2050, affecting more than 48 million individuals. 4 suggest an HbA 1c goal <7.0%. 6 Ultimately, as diabetes progresses, most patients will require insulin therapy. However, the purpose of this communication is to focus upon ways primarily to capitalize on non-insulin combination therapies to achieve glycemic goals.
Guidelines from the European Association for the Study of Diabetes (EASD) concur with the concept that utilization of polypharmacy, especially early combination therapy, is one of the greatest advances in DM2 disease management. 8 Skillful application of combination treatments will be necessary to attain and maintain adequate glucose control in the majority of DM2 patients. 9 For diabetic patients who "deselect" injection therapy (ie, those who are unwilling or unable to use parenteral treatments), it will be particularly necessary to capitalize upon the complementary therapeutic effects of multiple oral agents. and treatment augmentation or substitution was 14 months; for patients on sulfonylurea monotherapy (n=2517), the average duration was 20 months. 13 Thus, there remains a great, unmet need for prompt and effective intensification of diabetes management. Early combination therapy offers promise in this regard.
CONCERNS ABOUT THE CURRENT STATUS OF DIABETES CONTROL
Recognizing that many patients with DM2
languish for protracted periods with glucose levels well above the recognized toxic threshold, the most recent ADA/EASD algorithm has provided a pathway for more prompt control of hyperglycemia by indicating the propriety of introducing insulin as an early agent in combination therapy with metformin to achieve glucose management goals. 14 We do not dispute the advantages of prompt control or the efficiency of goal attainment with insulin.
Rather, we see great opportunity for improved recognition of the prompt glycemic control that can be attained with skillful combination of non-insulin therapies, and advancement of therapy with greater chronological alacrity. and all-cause mortality; these favorable results were found despite the fact that by the end of this observation period, HbA 1c levels in the group originally assigned to intensive treatment were essentially the same as the group originally assigned to conventional treatment. 19 Another important trial that showed benefits of glucose control in DM2 was the Kumamoto study. 20 In a population of 110 Japanese DM2 patients, retinopathy was reduced by 69% and nephropathy by 70% after 6 years of intensive glucose control to an HbA 1c level of 7.1%. 20 One of the often neglected benefits of good glucose control is the effect upon quality of life. Although motivation for patients to adhere to medication regimens may spring from a desire to avoid microvascular and macrovascular consequences, patients who feel better are directly rewarded for their efforts.
In a randomized, double-blind study of DM2 patients (n=569), subjects were assigned to active treatment (sulfonylurea) or placebo for 12 weeks, at which point numerous quality of life endpoints were compared. 21 Symptom distress, general perceived health, cognitive functioning, and overall visual analog scale improved in the treatment group, but worsened in the placebo group. Active treatment also had an impact on the number of work days missed. In their zeal to prevent "hard" endpoints, clinicians should not lose sight of the benefits on quality of life that may be achieved through good glucose control.
RELEVANT PATHOPHYSIOLOGY
DM2 is a progressive disorder; it appears that once beta-cell loss begins, the process continues indefinitely. 22 We know of no therapy that has Multiple pathologies are associated with diabetes, foremost of which (at least initially), appears to be insulin resistance. 24 As much as a decade before fasting or postprandial glucose becomes elevated (Figure 2 ), insulin resistance may be present. As long as increased beta-cell activity compensates for this insulin resistance, no derangement of fasting or postprandial glucose is evident.
It has been reported that by the time a diagnosis of DM2 has been made, 50% of beta-cell function has been lost. 26 
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Limitations of Current Monotherapies
Monotherapy is unlikely to maintain adequate (Table 3) . 37 We disagree with the most recent American amounting to an 80-mg/dL greater reduction than either monotherapy. 42 A longer-term study, the PRESERVE-Beta trial, 43 assessed the effects of glyburide or nateglinide plus metformin 
